From a third-party payer perspective, atypical antipsychotic mono-therapy generated higher drug costs but lower medical care costs, resulting in equivalent total healthcare costs over a 1-year period. </AbstractSection> Copyright Adis Data Information BV 2010

Background: A large body of clinical studies have demonstrated the efficacy of atypical antipsychotic use in the treatment of bipolar disorder. Facing increasing budget pressure, third-party payers, such as state Medicaid programmes in the US, are demanding better understanding of the medical...